Chronic hepatitis B virus (CHBV) affects more than 250 million individuals worldwide and is the dominant risk factor for hepatocellular carcinoma (HCC).
1,2 Nucleos(t)ide analogues reduce the risk of HCC in patients with CHBV by inhibiting viral replication and preventing fibrosis.
3-5 Tenofovir and entecavir are highly potent nucleos(t)ide analogues with high genetic barriers to resistance and are both recommended by major society guidelines as first-line agents for the treatment of patients with CHB at higher risk for disease progression.
6-11 However, the comparative effectiveness of tenofovir and entecavir in preventing HCC remains a matter of controversy and debate.
12